• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雄激素剥夺和放射治疗后,睾酮恢复时间延长对前列腺癌结局有利。

Longer time to testosterone recovery impacts favorably on outcomes for prostate cancer following androgen deprivation and radiotherapy.

机构信息

Dept. of Radiation Oncology, Complejo Hospitalario Universitario de Albacete (CHUA), C/ Hnos Falcó 37, 02006, Albacete, Spain.

Laboratorio de Oncología. Unidad de Medicina Molecular, Centro Regional de Investigaciones Biomédicas, Unidad Asociada de Biomedicina UCLM, Unidad asociada al CSIC, Universidad de Castilla-La Mancha, Albacete, Spain.

出版信息

Strahlenther Onkol. 2024 Aug;200(8):691-697. doi: 10.1007/s00066-024-02208-8. Epub 2024 Feb 28.

DOI:10.1007/s00066-024-02208-8
PMID:38416163
Abstract

PURPOSE

To evaluate the impact of sustained hypogonadism after androgen deprivation therapy (ADT) associated with radiotherapy in prostate cancer (PCa) patients with biochemical relapse-free survival (bRFS).

METHODS

A retrospective cohort analysis of 213 consecutive PCa patients referred for radiotherapy plus ADT was carried out. Follow-up times including time to testosterone recovery (TTR) and bRFS were calculated from the end of ADT. Univariate and multivariate Cox regression analyses predicting bRFS were used. The optimal cutoffs for TTR and duration of ADT were determined using the maximally selected rank statistics (MSRS).

RESULTS

After a median follow-up of 104 months, 18 patients relapsed among those who had recovered testosterone levels and 9 among those who did not. Median ADT duration was 36 months. The optimal cutoff for TTR was determined using MSRS. TTR >48 months was significantly associated with better bRFS (logrank, p < 0.0027). Five-year bRFS was 100% for >48 months vs. 85% for <48 months. TTR was the only significant variable for bRFS in multivariate Cox analysis.

CONCLUSION

Our data show an association between longer TTR and bRFS values among PCa patients treated with ADT.

摘要

目的

评估雄激素剥夺治疗(ADT)联合放疗后持续性性腺功能减退对前列腺癌(PCa)患者生化无复发生存(bRFS)的影响。

方法

对 213 例连续接受放疗加 ADT 的 PCa 患者进行回顾性队列分析。从 ADT 结束时开始计算随访时间,包括睾酮恢复时间(TTR)和 bRFS。使用单变量和多变量 Cox 回归分析预测 bRFS。使用最大选择秩统计(MSRS)确定 TTR 和 ADT 持续时间的最佳截止值。

结果

中位随访 104 个月后,在恢复睾酮水平的患者中有 18 例复发,在未恢复睾酮水平的患者中有 9 例复发。ADT 持续时间中位数为 36 个月。使用 MSRS 确定了 TTR 的最佳截止值。TTR >48 个月与更好的 bRFS 显著相关(logrank,p < 0.0027)。5 年 bRFS 为 >48 个月者为 100%,<48 个月者为 85%。TTR 是多变量 Cox 分析中唯一与 bRFS 显著相关的变量。

结论

我们的数据表明,接受 ADT 治疗的 PCa 患者的 TTR 与 bRFS 值之间存在关联。

相似文献

1
Longer time to testosterone recovery impacts favorably on outcomes for prostate cancer following androgen deprivation and radiotherapy.雄激素剥夺和放射治疗后,睾酮恢复时间延长对前列腺癌结局有利。
Strahlenther Onkol. 2024 Aug;200(8):691-697. doi: 10.1007/s00066-024-02208-8. Epub 2024 Feb 28.
2
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
3
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.放疗联合瑞戈非尼在局部晚期或转移性前列腺癌男性患者中的疗效和安全性。
JAMA Oncol. 2024 May 1;10(5):594-602. doi: 10.1001/jamaoncol.2023.7279.
4
PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study.双相雄激素治疗引起的 PSA 升高可能预测一线雄激素剥夺治疗的反应持续时间:BATMAN 研究的更新结果。
Prostate. 2022 Dec;82(16):1529-1536. doi: 10.1002/pros.24426. Epub 2022 Aug 8.
5
Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer: Secondary Analysis of a Randomized Clinical Trial.雄激素受体通路抑制剂治疗晚期前列腺癌:一项随机临床试验的二次分析
JAMA Netw Open. 2025 Jan 2;8(1):e2454253. doi: 10.1001/jamanetworkopen.2024.54253.
6
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer.联合固定疗程全身治疗与转移灶定向放疗用于寡转移激素敏感性前列腺癌
Eur Urol Oncol. 2025 Jun;8(3):709-715. doi: 10.1016/j.euo.2024.10.014. Epub 2024 Nov 14.
7
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.恩杂鲁胺与达罗他胺双重疗法在转移性去势敏感性前列腺癌中的匹配调整间接比较
Future Oncol. 2025 Aug;21(19):2459-2469. doi: 10.1080/14796694.2025.2526324. Epub 2025 Jul 14.
8
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.对于开始接受雄激素剥夺治疗的转移性前列腺癌患者使用二甲双胍:STAMPEDE平台方案的一项随机3期试验
Lancet Oncol. 2025 Jul 7. doi: 10.1016/S1470-2045(25)00231-1.
9
pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post-Initiation of Androgen Deprivation Therapy.在雄激素剥夺治疗开始后,晚期前列腺癌中磷酸化信号转导及转录激活因子3(pSTAT3)的表达增加。
Prostate. 2025 Feb;85(3):252-264. doi: 10.1002/pros.24820. Epub 2024 Nov 11.
10
Castration Levels of Testosterone Results in Atrophy of Androgen-sensitive Perineal Muscles: A Potential Biomarker for Male Hypogonadism.睾酮的去势水平导致雄激素敏感的会阴肌肉萎缩:一种男性性腺功能减退的潜在生物标志物。
Urology. 2025 Feb;196:313-320. doi: 10.1016/j.urology.2024.10.006. Epub 2024 Oct 18.

本文引用的文献

1
Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial.雄激素剥夺联合大剂量放疗后睾酮去势水平对局限性前列腺癌的预后价值:一项III期试验的结果
Radiother Oncol. 2021 Jul;160:115-119. doi: 10.1016/j.radonc.2021.04.018. Epub 2021 May 5.
2
Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.雄激素剥夺疗法治疗前列腺癌后睾酮的恢复情况。
J Sex Med. 2019 Jun;16(6):872-879. doi: 10.1016/j.jsxm.2019.03.273. Epub 2019 May 9.
3
A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer.
前列腺癌雄激素剥夺联合放射治疗后睾酮恢复的列线图
Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):834-842. doi: 10.1016/j.ijrobp.2018.11.007. Epub 2018 Nov 10.
4
Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results.局限性前列腺癌的侵袭性:通过总睾酮和生物可利用睾酮评估的睾酮缺乏的关键价值:AndroCan 研究结果。
Horm Cancer. 2019 Feb;10(1):36-44. doi: 10.1007/s12672-018-0351-8. Epub 2018 Oct 6.
5
Eighteen Months of Androgen Deprivation Therapy in Men with High-risk Prostate Cancer and the Risk of Death.
Eur Urol. 2018 Oct;74(4):442-443. doi: 10.1016/j.eururo.2018.06.026. Epub 2018 Jul 2.
6
Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis.睾酮水平与前列腺癌预后:系统评价和荟萃分析。
Clin Genitourin Cancer. 2018 Jun;16(3):165-175.e2. doi: 10.1016/j.clgc.2018.01.005. Epub 2018 Feb 2.
7
Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.雄激素反弹时间和合并症对预后不良前列腺癌患者特定原因死亡率风险的影响。
Cancer. 2018 Apr 1;124(7):1391-1399. doi: 10.1002/cncr.31217. Epub 2018 Jan 16.
8
Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.睾酮替代疗法与良性及侵袭性前列腺癌风险
J Clin Oncol. 2017 May 1;35(13):1430-1436. doi: 10.1200/JCO.2016.69.5304. Epub 2017 Mar 13.
9
Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk.睾酮与前列腺癌:基于证据的发病机制与肿瘤风险综述
Ther Adv Urol. 2015 Dec;7(6):378-87. doi: 10.1177/1756287215597633.
10
Does degree of androgen suppression matter in hormone-sensitive prostate cancer?雄激素抑制程度在激素敏感性前列腺癌中重要吗?
J Clin Oncol. 2015 Apr 1;33(10):1098-100. doi: 10.1200/JCO.2014.60.1419. Epub 2015 Mar 2.